NT5DC2的下调抑制了单胺氧化酶的活性,并促进了PC12D细胞中的甲醇胺合成
Hisateru Yamaguchi1,2, Miho Kawata3, Yu Kodani3
1Department of Physiological Chemistry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
Molecular biology reports
|August 2, 2025
概括
5'-核酶域含有蛋白2 (NT5DC2) 调节单氨酸氧化酶A (MAO A) 的活性,影响着甲醇胺的代谢. 这一发现为神经精神疾病和帕金森病提供了新的见解.
科学领域:
- 神经生物学 神经生物学 神经生物学
- 生物化学 生物化学
- 分子生物学分子生物学
背景情况:
- 全基因组关联研究将NT5DC2与神经精神疾病联系起来.
- 目前尚不清楚NT5DC2在甲醇胺合成中的确切功能.
- 之前的研究表明,NT5DC2会影响氨酸氧酶 (TH) 活性.
研究的目的:
- 研究NT5DC2在调节单胺氧化酶A (MAO A) 活性中的作用.
- 为了确定NT5DC2对PC12D细胞中catecholamine代谢的影响.
主要方法:
- 利用siRNA降低PC12D细胞中NT5DC2表达的调节.
- 在多巴胺添加和TH抑制后分析了甲基胺和代谢物水平.
- 雇佣了Western blot来评估NT5DC2对MAO A具有约束力.
主要成果:
- 发现NT5DC2主要与MAO A.的非酸化形式结合.
- NT5DC2降低调节降低了MAO A活动.
- 降低MAO A活性导致多巴胺代谢降低,上腺素合成增加.
结论:
- NT5DC2在MAO A活性中起着调节作用,从而控制着甲醇胺合成.
- 研究结果提供了关于帕金森病和神经精神疾病中甲基胺失调的见解.
相关概念视频
Drugs Affecting Neurotransmitter Synthesis
1.6K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.6K
Drugs Affecting Neurotransmitter Release or Uptake
1.2K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.2K
Receptor Downregulation in MVBs
2.1K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.1K
Adrenergic Agonists: Indirect-Acting Agents
1.8K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.8K
Adrenergic Neurons: Neurotransmission
4.1K
Postganglionic sympathetic fibers (except those supplying the sweat glands) releasing noradrenaline or norepinephrine are called noradrenergic or adrenergic neurons. Noradrenaline, dopamine, adrenaline, or epinephrine are collectively called "catecholamines" as they contain a catechol moiety and an amine side chain. The five stages of neurotransmitter release involve their synthesis, storage, release, reuptake and metabolism.
Synthesis: Catecholamine synthesis requires tyrosine, which...
Synthesis: Catecholamine synthesis requires tyrosine, which...
4.1K
Desensitization and Tachyphylaxis
2.2K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
2.2K


